Bisphosphonates - Pediatric use;Bisphosphonate - Anwendung in der padiatrie

Monatsschrift fur Kinderheilkunde

Volumn 148, Issue 4, 2000, Pages 334-341

  Rauch, F ^a,b,c   Schonau E ^b   Glorieux, F H ^a,b,c  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bisphosphonates; Bone turnover; Metabolic osteopathy; Osteogenesis imperfecta

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID;

BONE DEVELOPMENT; BONE RADIOGRAPHY; BONE TURNOVER; CHILD; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG STRUCTURE; HUMAN; HYPERCALCEMIA; METABOLIC BONE DISEASE; OSTEOGENESIS IMPERFECTA; REVIEW;

EID: 0342749310     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001120050556     Document Type: Review

References (63)

1. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
2. Adami S, Zamberlan N (1996) Adverse effects of bisphosphonates. A comparative review. Drug Saf 14:158-170
3. Allgrove J (1997) Bisphosphonates. Arch Dis Child 76:73-75
4. Allgrove J (1996) Bisphosphonates: paediatric indications - advantages and possible side effects. In: Schönau E (ed) Paediatric osteology: new developments in diagnostics and therapy. Elsevier, Amsterdam New York, pp 261-273
5. Basset CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD (1969) Disphosphonates in the treatment of myositis ossificans. Lancet 2:845
6. Bishop NJ, Plotkin H, Travers R, Lanoue G, Rauch F, Glorieux FH (1998) Effect of two years of pamidronate treatment in children with polyostotic fibrous dysplasia. Bone 22:54S
7. Bishop NJ, Williams DM, Compston JC, Stirling DM, Prentice A (1995) Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol 89:927-928
8. Boudailliez BR, Pautard BJ, Sebert JL, Kremp O, Piussan CX (1990) Leukaemia-associated hypercalcaemia in a 10-yearl-old boy: effectiveness of aminohydroxypropylidene bisphosphonate. Pediatr Nephrol 4:510-511
9. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F (1983) Renal failure associated with intravenous disphosphonates. Lancet 1:471
10. Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283
11. Cassinelli HR, Mautalen CA, Heinrich JJ, Miglietta A, Bergada C (1992) Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD). Bone Miner 19:175-184
12. Chapurlat RD, Delmas PD, Liens D, Meunier PJ (1997) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746-1752
13. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021
14. Delmas PD (1996) Bisphosphonates in the treatment of bone diseases. N Engl J Med 335:1836-1837
15. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363
16. Falcini F, Trapani S, Ermini M, Brandi ML (1996) Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 58:166-169
17. Fleisch H (ed) (1997) Bisphosponates in bone disease. From the laboratory to the patient, 3rd edn. Parthenon Publishing Group, New York
18. Fleisch H (1998) Bisphosphonates: mechanism of action. Endocr Rev 19:80-100
19. Flora L, Hassing GS, Cloyd GG, Bevan JA, Parfitt AM, Villanueva AR (1981) The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 3:289-300
20. Frost HM, Ferretti JL, Jee WS (1998) Perspectives: some roles of mechanical usage, muscle strength, and the mechanostat in skeletal physiology, disease, and research. Calcif Tissue Int 62:1-7
21. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
22. Glorieux FH, Norman ME, Travers R, Taylor A (1993) Idiopathic juvenile osteoporosis. In: Christiansen C, Rijs B (eds) Proceedings. Fourth International Symposium on Osteoporosis and Consensus Development Conference, Hongkong, pp 200-202
23. Gutteridge DH, Retallack RW, Ward LC, Stuckey BG, Stewart GO, Prince RL, Kent GN, Bhagat CI, Price RI, Thompson RI, Nicholson GC (1996) Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. Bone 9:387-394
24. Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL (1985) Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61:952-956
25. Kedlaya D, Brandstater ME, Lee JK (1998) Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate. Arch Phys Med Rehabil 79:222-225
26. Kutluk MT, Hazar V, Akyuz C, Varan A, Buyukpamukcu M (1997) Childhood cancer and hypercalcemia: report of a case treated with pamidronate. J Pediatr 130:828-831
27. Lepola VT, Kippo K, Hannuniemi R, Lauren L, Virtamo T, Osterman T, Jalovaara P, Sellman R, Vaananen HK (1996) Bisphosphonates clodronate and etidronate in the prevention of ovariectomy-induced osteopenia in growing rats. J Bone Miner Res 11:1508-1517
28. Lepore L, Pennesi M, Barbi E, Pozzi R (1991) Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol [Suppl 6] 9:33-35
29. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85
30. Lteif AN, Zimmerman D (1998) Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 102:990-993
31. Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220-224
32. McIntyre HD, Cameron DP, Urquhart SM, Davies WE (1989) Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J 65:244-246
33. Morike M, Brenner RE, Bushart GB, Teller MW, Vetter U (1992) Collagen metabolism in cultured osteoblasts from osteogenesis imperfecta patients. Biochem J 286:73-77
34. Mundy GR, Yoneda T (1998) Bisphosphonates as anticancer drugs. N Engl J Med 339:398-400
35. Ostlere L, Warner T, Meunier PJ, Hulme P, Hesp R, Watts RW, Reeve J (1991) Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). QJM 79:503-515
36. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150-159
37. Pietschmann P, Stohlawetz P, Brosch S, Steiner G, Smolen JS, Peterlik M (1998) The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 63:325-330
38. Plotkin H, Rauch F, Lanoue G, Travers R, Glorieux FH (1998) Severe osteogenesis imperfecta: effect of one year of pamidronate (APD) treatment in children under two years of age. Bone 23:S192
39. Profumo RJ, Reese JC, Foy TM, Garibaldi LR, Kane RE (1994) Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate. Transplantation 57:301-303
40. Rawlinson PS, Green RH, Coggins AM, Boyle IT, Gibson BE (1991) Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation. Arch Dis Child 66:638-639
41. Reading PJ, Newman PK, Kelly WF, Bateson MC, Rothwell P (1997) Treatment of immobilisation hypercalcaemia in acute intermittent porphyria: experience from three cases. J Neurol Neurosurg Psychiatry 62:421-422
42. Reynolds JJ, Murphy H, Muhlbauer RC, Morgan DB, Fleisch H (1973) Inhibition by disphosphonates of bone resorption in mice and comparison with grey-lethal osteopetrosis. Calcif Tissue Res 12:59-71
43. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P (1997) Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 151:1587-1600
44. Ringel MD, Schwindinger WF, Levine MA (1996) Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine 75:171-184
45. Rodan GA (1997) Bone mass homeostatis and bisphosphonate action. Bone 20:1-4
46. Rowe DW, Shapiro JR (1998) Osteogenesis imperfecta. In: Avioli LV, Krane SM (eds) Metabolic bone disease and clinically related disorders, 3rd edn. Academic Press, San Diego, pp 651-695
47. Saag KG, Emkey R, Schnitzer TJ, Brown JR Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MR Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299
48. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA (1994) Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clincal skeletal manifestations of Gaucher's disease. Pediatrics 94:385-389
49. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105
50. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud P (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133-139
51. Schenk R, Merz WA, Muhlbauer R, Russell RG, Fleisch H (1973) Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene disphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196-214
52. Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349
53. Schönau E, Rauch F (1997) Markers on bone and collagen metabolism - problems and perspectives in paediatrics. Horm Res [Suppl 5] 48:50-59
54. Seeman E (1997) From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res 12:509-521
55. Shaw NJ, White CP, Fraser WD, Rosenbloom L (1994) Osteopenia in cerebral palsy. Arch Dis Child 71:235-238
56. Singer F, Siris E, Shane E, Dempster D, Lindsay R, Parisien M (1994) Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. J Bone Miner Res 9:733-738
57. Spindler A, Berman A, Mataulen C, Ubios J, Santini AE (1992) Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature. J Rheumatol 19:642-645
58. Takagi M, Takahiashi K, Maruyama T, Kaneko K, Obinata K, Tadokoro R, Kastumata K, Miura Y, Fujita H, Tokita A, Ishimoto K, Yabuta K (1998) Acute lymphoblastic leukemia accompanied by severe hypercalcemia: successful treatment including aminohydroxypropylidene bisphosphonate (pamidronate disodium). Pediatr Hematol Oncol 15:283-286
59. Van Persijn van Meerten EL, Kroon HM, Papapoulos SE (1992) Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 184:249-254
60. Varache N, Audran M, Clochon P, Lortholary A, Bouachour G, Alquier P, Basle MF (1991 ) Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient. Clin Rheumatol 10:328-332
61. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
62. Yamaguchi K, Grant J, Noble-Jamieson G, Jamieson N, Barnes ND, Compston JE (1995) Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate. Bone 16:61-67
63. Young G, Shende A (1998) Use of pamidronate in the management of acute cancer-related hypercalcaemia in children. Med Pediatr Oncol 30:117-121